Table 1.

Characteristics of 18 studies assessing combination of cisplatin/gemcitabine.

First author	Type of study	Overall patient number	Year of publication	Patients number by arm	Chemotherapy regimen	Dose (mg/m²)	Treatment schedule	Treatment duration
Carraro [12]	Phase II	11	2001	11	Cisp + Gem	30 + 1000	d1d8d15/d1d8d15-q4w	NA
Malik [13]	Phase II	11	2003	11	Cisp + Gem	70 + 1000	d1/d1d8-q3w	Until DP or UT
Baluch [14]	Phase II	14	2003	14	Cisp + Gem	60 + 1000	d1/d1d8-q3w	NA
Reyes-Vidal [15]	Phase II	44	2003	44	Cisp + Gem	35 + 1250	d1d8/d1d8-q3w	NA
Doval [16]	Phase II	30	2004	30	Cisp + Gem	70 + 1000	d1/d1d8-q3w	Six cycles unless DP or UT
Thongprasert [17]	Phase II	43	2005	43	Cisp + Gem	75 + 1250	d1/d1d8-q3w	Until DP or UT
Kim [18]	Phase II	29	2006	29	Cisp + Gem	60 + 1250	d1/d1d8-q3w	Until DP
Giuliani [19]	Phase II	38	2006	38	Cisp + Gem	80 + 1000	d1/d1d8-q3w	Six cycles unless DP or UT
Park [20]	Phase II	27	2006	27	Cisp + Gem	75 + 1000	d1/d1d8d15-q4w	NA
Lee [21]	Phase II	24	2006	24	Cisp + Gem	70 + 1000	d1/d1d8-q3w	Until DP or UT
Meyerhardt [22]	Phase II	33	2007	33	Cisp + Gem	30 + 1000	d1d8/d1d8-q3w	Until DP or UT
Charoentum [23]	Retrospective study	42	2007	42	Cisp + Gem	75 + 1250	d1/d1d8-q3w	NA
Lee [21]	Phase II	35	2008	35	Cisp + Gem	70 + 1250	d1/d1d8-q3w	Eight cycles
Valle [24]	Randomized comparative Phase II	86	2009	42	Cisp + Gem	25 + 1000	d1d8/d1d8-q3w	Eight cycles unless DP or UT
				44	Gem	1000	d1d8d15-q4w	Six cycles unless DP or UT
Goldstein [25]	Phase II	50	2010	50	Cisp + Gem	20 + 1000	d1d8/d1d8-q3w	Until DP or UT
Okusaka [26]	Randomized comparative Phase II	83	2010	41	Cisp + Gem	25 + 1000	d1d8/d1d8-q3w	Sixteen cycles unless DP or UT
				42	Gem	1000	d1d8d15-q4w	Twelve cycles unless DP or UT
Valle [8]	Phase III	410	2010	204	Cisp + Gem	25 + 1000	d1d8/d1d8-q3w	Eight cycles unless DP or UT
				206	Gem	1000	d1d8d15-q3w	Six cycles unless DP or UT
Weatherly [27]	Retrospective study	85	2011	53	Cisp + Gem	NA	NA	NA
				32	“Alternative” regimens	NA	NA	NA

DP, disease progression; UT, unacceptable toxicity.